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Abstract
Background: In dogs in the western world neoplasia constitutes the most frequently diagnosed
cause of death. Although there appear to be similarities between canine and human cancers, rather
little is known about the cytogenetic and molecular alterations in canine tumours. Different dog
breeds are susceptible to different types of cancer, but the genetic basis of the great majority of
these predispositions has yet to be discovered. In some retriever breeds there is a high incidence
of soft tissue sarcomas and we have previously reported alterations of chromosomes 11 and 30 in
two poorly differentiated fibrosarcomas. Here we extend our observations and present a case
report on detail rearrangements on chromosome 11 as well as genetic variations in a tumour
suppressor gene in normal dogs.
Results:  BAC hybridisations on metaphases of two fibrosarcomas showed complex
rearrangements on chromosome 11, and loss of parts of this chromosome. Microsatellite markers
on a paired tumour and blood DNA pointed to loss of heterozygosity on chromosome 11 in the
CDKN2B-CDKN2A  tumour suppressor gene cluster region. PCR and sequencing revealed the
homozygous loss of coding sequences for these genes, except for exon 1β of CDKN2A, which codes
for the N-terminus of p14ARF. For CDKN2B exon 1, two alleles were observed in DNA from blood;
one of them identical to the sequence in the dog reference genome and containing 4 copies of a 12
bp repeat found only in the canine gene amongst all species so far sequenced; the other allele was
shorter due to a missing copy of the repeat. Sequencing of this exon in 141 dogs from 18 different
breeds revealed a polymorphic region involving a GGC triplet repeat and a GGGGACGGCGGC
repeat. Seven alleles were recorded and sixteen of the eighteen breeds showed heterozygosity.
Conclusion: Complex chromosome rearrangements were observed on chromosome 11 in two
Labrador retriever fibrosarcomas. The chromosome alterations were reflected in the loss of
sequences corresponding to two tumour suppressor genes involved in cell-cycle progression.
Sequencing of CDKN2B across many different breeds revealed a widespread polymorphism within
the first exon of the gene, immediately before the ankyrin coding sequences.
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Background
Neoplasia is profoundly important as a cause of morbid-
ity and mortality in the domestic dog, Canis lupus famil-
iaris. In addition to its importance as a working animal
and a pet species, the dog is an important intermediate
model species for human tumour biology. It has a rela-
tively large body size, often displays responses to cytotoxic
or other therapeutic agents comparable to humans, and
has a relatively high natural incidence of several cancers
with similar biology to human tumours. Dogs have been
used as models for cancer therapy, such as in osteosar-
coma, in the giant dog breeds, oral melanoma and non-
Hodgkins lymphoma, amongst others (reviewed in [1,2].
In general, the same tumour types are recognised in
humans and dogs; for instance, the classification of soft
tissue sarcomas of dogs largely follows the human system
[3]. Studies of cytogenetic and genetic changes in canine
soft tissue sarcomas may reveal more about their aetiol-
ogy.
In a previous study, primary cell cultures were obtained
from two poorly differentiated fibrosarcomas [4]. Both
tumours (which were name-coded LE and ME) came from
adult female Labrador retrievers. Chromosome painting
revealed they both had abnormalities in chromosomes 11
(CFA11) and 30 (CFA30). One tumour (LE) contained
four translocation chromosomes involving CFA4, CFA11,
CFA27 and CFA30 (tumour karyotype 2n = 78; t(4;11;30),
t(11;27); t(27;11); t(30;4); der 11 (del 11q)); the second
one (ME) had a deletion of CFA11q and trisomy of CFA30
(tumour karyotype 2n = 79; der11; +30). An attempt to
isolate the translocation chromosomes by Fluorescence
Activated Chromosome Sorting had not allowed com-
plete purification of these chromosomes but PCR of
sequence tagged sites (STS), on sorted preparations, had
shown that sequences in the first 7 Mb of CFA 27 and the
last 20 Mb of CFA11 were present in the LE tumour
genome, but missing when t(27;11) was excluded. Rear-
rangement in the Transforming Growth Factor Beta
Receptor 1 gene (TGFBR1) was implied as only a portion
of the exonic sequences could be obtained by PCR of DNA
in this preparation. In addition to this altered copy of
TGFBR1, the tumour still had at least one normal coding
sequence of the gene. This tumour sequence was identical
to that obtained from blood DNA of the same individual.
At least one normal coding sequence of TGFBR1 was also
present in the tumour ME. Here we extend our search for
molecular alterations of CFA11 that could be linked to
canine sarcomas and present a case report involving the
loss of heterozygosity in a region harbouring two tumour
suppressor genes.
Results
Further characterisation of derivative chromosomes by 
BAC hybridisation
To obtain a more detailed description of rearrangements
in chromosome 11 in these fibrosarcomas, eleven canine
BACs spaced at intervals along chromosome 11 were used
to probe tumour metaphases, in some cases in combina-
tion with chromosome paints identifying translocation
partners (Table 1). For LE, the distribution of BAC hybrid-
isation suggests that the der11 and t(4;11;30) chromo-
somes originate from one chromosome 11 whilst
t(11;27) and t(27;11) originate from the other (Figure 1).
However, the pattern of rearrangements in derivative
chromosomes is complex. The der11 chromosome con-
tains both centromeric and telomeric sequences in an
inverted arrangement, whilst central parts of this chromo-
some 11 are found in t(4;11;30) (BACs between 375-F21
and 381-N7 locate here). t(11;27) contains the centro-
mere proximal region of CFA11. Although no BACs more
telomeric than 375-F21 hybridised to this chromosome,
chromosome painting suggests that more than half of the
normal CFA11 is present, so there may be some further
interstitial insertion of sequences not represented by the
BACs used here. More telomeric BACs hybridised to
t(27;11) but, again, these showed rearrangement such
that 381-H22 has a sub-telomeric position whilst BACs
which lie distal to this in the normal chromosome are
now placed near the centre of the derivative. The translo-
cation break/fusion point is close to RP81_381-N7 with
BACs derived from centromere proximal sequence found
distal to this position in the fusion chromosome.
For ME, BACs telomeric of RP81_381-H22 did not hybrid-
ise to the derivative chromosome, but RP81_381-H22
itself did (Figure 2). There was also lack of signal from
RP81_376-M15 on the derivative, suggesting interstitial
deletion of the derivative chromosome in the area of this
BAC. In independent RH mapping studies the BAC 381-
F14 is placed on chromosome 11 at position 8810, telom-
eric to 373M14 [5].
Loss of heterozygosity
For LE, genomic DNA from blood and tumour was avail-
able, while only tumour DNA could be obtained for sam-
ple ME. Loss of heterozygosity on CFA11 was analysed for
the LE fibrosarcoma. Forty-five microsatellites distributed
across the chromosome were studied (Table 2). Complete
loss of heterozygosity (loss of the 262 bp allele) was
observed for marker CAMC11.029, and a substantial loss
(of the 224 bp allele) for marker CAMC11.026 (22%
remaining signal) (see Figure 3). The region between these
two markers contains sequences orthologous to the
human genes coding for the proteins p15INK4B, p16INK4A
and p14ARF. The first one is coded by the cyclin-dependent
kinase inhibitor 2B gene (CDKN2B), while the other twoBMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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are coded by cyclin-dependent kinase inhibitor 2A
(CDKN2A) [reviewed in [6]]. A marker (CAMC11.027)
within the canine CDKN2B-CDKN2A region was unin-
formative (homozygous in blood and tumour DNA for
sample LE). Most other markers showed no change
between tumour and blood, but one further marker,
(FH4031, 29.9 Mb proximal from CAMC11.026), showed
partial loss of one allele (37% remaining signal). For
marker CAMC11.004 (10 Mb from CAMC11.026) a dis-
crepancy was observed in the results corresponding to the
blood and the tumour; the former presented a hetero-
zygous genotype, while the tumour had a single allele that
was different to either of those observed in the blood.
CDKN2B and CDKN2A sequencing from tumour DNA
CDKN2A and CDKN2B have not been fully described in
the dog. No mRNAs or ESTs that completely define these
genes are available, and gene prediction programmes do
not fully agree with each other or with those EST that are
available. In addition, the area is extremely GC rich and
has proved difficult to clone or to sequence, containing a
gap in the CamFam 2.0 genome assembly [7,8]. Align-
ments with human and other CDKN2A/B RNAs appear to
be the best guide to gene structure. We used these to
design PCR primers. To determine whether the expected
remaining copy of these genes had any mutations in
tumour LE, the predicted exonic sequences, and their
flanking intronic sequences, were investigated. Since the
gap in the dog reference sequence is where CDKN2A exon
1α is expected to be present (Table 2 and Figure 3), it was
not studied. However, a PCR product could be obtained
for the predicted exon 1β; this sequence was identical to
that observed in blood DNA from the same individual,
and to the sequence in the reference genome. In contrast
to this, for CDKN2A no PCR products of exon 2 could be
obtained from tumour LE's DNA in spite of repeated
attempts, but the sequence was obtained from blood DNA
and it contained no difference when compared to the ref-
erence genome.
When using DNA from tumour as template, no PCR prod-
ucts could be obtained for CDKN2B exons 1 and 2 and
their flanking intronic sequences. In LE's DNA from
blood, the sequence of CDKN2B exon 2 was the same as
in the reference genome. Exon 1 of this same gene could
not be PCR-amplified from tumour LE but it was ampli-
fied using DNA from blood, and then cloned and
sequenced. The results showed that this individual was
heterozygous, having one allele with the same sequence as
the reference genome (g. [109GGC[5];
124GGGGACGCCGCC[4]]) as well as a shorter allele (g.
[109GGC[5]; 124GGGGACGCCGCC[3]]). At the amino
acid level the first allele would have five Gly residues fol-
lowed by four tandem copies of the sequence GlyAspGly-
Gly (p. [Gly10[5]; Gly15_Gly18[4]]), while the second
allele would consist of five Gly followed by only 3 copies
Table 1: BACs used for in situ hybridisation.












386-H9 11 6153594 + + +
385-C1 11 22151575 NA* NA NA +
375-F21 11 24354423 + + +
372-O3 11 32432415 + + +
372-K9 11 33384887 NA NA NA +
381-N7 11 41509254 + + +
376-M15 11 46649071 NA NA NA -
381-H22 11 49355967 + + +
373-C5 11 59457191 + + -
373-M14 11 65702272 NA NA NA -
381-F14 27 38704742 + + -
*NA = Data not available.BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
Page 4 of 18
(page number not for citation purposes)
of the tetrapeptide (p. [Gly10[5]; Gly15_Gly18[3]]) (Fig-
ure 4).
CDKN2B exon 1 polymorphism in the dog
To investigate whether the shorter allele could be related
to the development of the neoplasia, the exon was was
amplified using DNA from blood of 141 dogs of 18 differ-
ent breeds. The size of the PCR products was determined
by capillary electrophoresis and products corresponding
to the different sizes were sequenced directly (Figure 5).
Seven different alleles were found (see Figure 6, and Addi-
tional file 1: Distribution of CDKN2B exon 1 alleles in
various dog breeds). The most frequent allele was p.
[Gly10[5]; Gly15_Gly18[4]], which corresponds to the
reference sequence and was found in all breeds studied.
Alleles p. [Gly10[5]; Gly15_Gly18[3]] and p. [Gly10[4];
Gly15_Gly18[4]] were also observed. Additionally, 4 alle-
les were rarer in this sample set; the shortest being p.
[Gly10[4]; Gly15_Gly18[2]] in Cardigan Welsh corgis,
and the longest p. [Gly10[5]; Gly15_Gly18[5]] in a Rott-
weiler. Among these blood samples, 24 corresponded to
flat-coated retrievers; of these 11 had histiocytic sarcoma
and 13 were non-affected dogs aged 10 years or more (See
Additional file 1: Distribution of CDKN2B exon 1 alleles
in various dog breeds). The distribution of the alleles was
not significantly different between these two sets (chi-
square test p = 0.55). All breeds except boxer (15 individ-
uals examined) and Shih Tzu (two individuals only) were
polymorphic at this position
Other CDKN2B and CDKN2A polymorphisms in the dog
To search for additional polymorphisms in these two
genes, exon 2 of CDKN2B was studied using DNA from
blood samples from a Bernese mountain dog, four boxers,
nine flat-coated retrievers (four with histiocytic sarcoma
and five free from neoplasia), two golden retrievers and a
Labrador retriever. No polymorphisms were seen in the
coding region or the flanking intronic bases.
Exon 2 of CDKN2A  was also sequenced from DNA
obtained from blood samples from three Bernese moun-
tain dogs, four flat-coated retrievers with histiocytic sar-
coma, and five flat-coated retrievers free from tumours,
two golden retrievers and four Labrador retrievers. A cod-
Chromosome painting of metaphases spreads from canine fibrosarcoma LE Figure 1
Chromosome painting of metaphases spreads from canine fibrosarcoma LE. Chromosome painting of tumour LE (6 
colour paints, colours as shown) shows 4 derivative chromosomes containing CFA11 DNA. To look at the distribution of 
CFA11 BACs, metaphases were hybridised with a mixed paint of CFA 4, 27 and 30 (green) and a single BAC paint as indicated 
in examples shown, (red). For N7, where the t(27;11) is difficult to identify because of a high green background, additional 
hybridising chromosomes from other metaphases are shown; inset at twice the scale. Diagrams summarise hybridisation of all 
BACs with each derivative containing chromosome 11. The red arrowheads denote BACs consistently binding to the chromo-
somes shown. Chromosomes in the diagram are CFA11 in blue (mid blue -centromeric; light blue -telomeric); CFA27 green; 
CFA4 yellow; CFA30 purple.BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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ing SNP was identified that led to a non-synonymous
change in the predicted codon 19 of exon 2 that is shared
by both p16INK4A and p14ARF. The polymorphism was a
g.1206A>G transversion that corresponds to a p.Gln79Arg
change in the predicted amino acid sequence of p14ARF
(Figure 7) and an Asn to Asp change in the p16INK4A read-
ing frame (Figure 8). Both alleles were found in all breeds
studied, except in the boxer where all four individuals
were homozygous for the reference sequence. In the flat-
coated retrievers half of the histiocytic sarcoma cases were
GG homozygous and the rest AG heterozygous, while two
controls were homozygous GG and three were hetero-
zygous.
Discussion
A previous analysis of two canine fibrosarcomas with rear-
rangement of chromosome 11 was followed up by BAC
mapping. In both tumours this revealed that rearrange-
ments were more complex than had been seen using chro-
mosome painting. In LE all chromosomes containing
fragments of chromosome 11, except t(11;27), showed
interstitial deletions and or rearrangements. In ME a dele-
tion around BAC M15 was observed. Loss of heterozygos-
ity (LOH) on chromosome 11 was studied in LE's tumour.
Marker CAMC011.004 (34.56 Mb) presented an allele in
the tumour which was different from any of those in the
blood. This result was confirmed in two independent
experiments. This marker is within a gene desert, with no
proven transcripts encoded or genes modelled within
about a megabase. Our data does not show whether this
marker is close to a rearrangement. FH4031 (14.24 Mb),
which shows LOH, is also some way from the nearest
known gene. In this case more proximal markers are not
informative. It seems likely that, in the tumour, the der11
and t(4;11;30) chromosomes have lost some sequences in
this region, which is near the proximal chromosome
breakpoint in both.
Loss of heterozygosity was also observed in two markers
which bracket a region encompassing the CDKN2B-
Chromosome painting of metaphases spreads derived from fibrosarcoma ME Figure 2
Chromosome painting of metaphases spreads derived from fibrosarcoma ME. Chromosome painting of tumour ME 
(6 colour paints, colours as shown) shows a der11 with ± 40% of the genomic material of the normal chromosome. An exam-
ple BAC hybridisation is shown, using RP81_381-N7 (red). Diagrams of the normal and derivative chromosome show hybridi-
sation positions of BACs: red arrowheads – BACs consistently binding to both chromosomes; green arrowheads -those not 
hybridising to the derivative; blue arrowhead -consistent hybridisation to the normal but inconsistent to the der 11 chromo-
some.BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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Table 2: CFA11 loss of heterozygosity.
Feature* Sequence type Mb Distance From Top LE blood genotype§ LE tumour genotype Observations
CAMC11.009 Microsatellite 4.985028 387, 387 387, 387
AHT137 Microsatellite 5.829562 148, 148 148, 148
REN161P13 Microsatellite 7.106779 189, 189 189, 189
CAMC11.008 Microsatellite 8.593416 195, 195 195, 195
FH3203 Microsatellite 8.623136 89, 89 89, 89
CAMC11.010 Microsatellite 11.425726 307, 307 307, 307
FH4031 Microsatellite 14.237434 312, 331 312, 331 LOH
REN286P10 Microsatellite 17.844923 182, 185 182, 185
REN242K04 Microsatellite 19.23201 328, 328 328, 328
CAMC11.022 Microsatellite 20.94395 164, 169 164, 169
CAMC11.021 Microsatellite 24.758282 242, 250 242, 250
REN142O09 Microsatellite 26.338024 256, 261 256, 261
CAMC11.020 Microsatellite 29.356331 332, 332 332, 332
CAMC11.001 Microsatellite 31.434645 264, 264 264, 264
FH2004 Microsatellite 32.161602 240, 240 240, 240
CAMC11.003 Microsatellite 33.777804 285, 285 285, 285
FH2710 Microsatellite 34.47053 187, 187 187, 187
CAMC11.004 Microsatellite 34.561666 247, 363 249, 249
FH2874 Microsatellite 35.143202 177, 177 177, 177
CAMC11.005 Microsatellite 35.801351 327, 327 327, 327
CAMC11.006 Microsatellite 36.813802 321, 325 321, 325
FH2319 Microsatellite 37.54361 304, 334 304, 334
FH2982 Microsatellite 41.069406 361, 379 361, 379
CAMC11.019 Microsatellite 41.843895 243, 243 243, 243
FH2706 Microsatellite 43.991845 201, 201 201, 201
CAMC11.026 Microsatellite 44.172674 224, 226 224, 226 LOH
CDKN2A Gene, exon 2 44.255474 Present Missing
Contig_16328 contig end 44.258553BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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Gap in dog sequence 44.258554
CDKN2A Gene, exon 1α Undetermined
Gap in dog sequence 44.260435
Contig_16329 contig start 44.260436
CDKN2A Gene, exon 1β 44.280332 Present Present
CAMC11.027 Microsatellite 44.288351 306, 306 306, 306
CDKN2B Gene, exon 2 44.291018 Present Missing
CDKN2B Gene, exon 1 44.293951 Heterozygous Missing
CAMC11.029 Microsatellite 44.304276 256, 262 256, 256 LOH
CAMC11.017 Microsatellite 45.277711 207, 238 207, 238
C11.868 Microsatellite 48.547399 216, 216 216, 216
CAMC11.016 Microsatellite 50.214468 223, 223 223, 223
CAMC11.015 Microsatellite 52.827522 209, 213 209, 213
CAMC11.014 Microsatellite 55.676158 268, 268 268, 268
FH2019 Microsatellite 56.07231 211, 211 211, 211
FH3238 Microsatellite 57.734062 276, 276 276, 276
REN249L05 Microsatellite 58.631801 175, 175 175, 175
TGFBR1 Gene 59.220624
CAMC11.024 Microsatellite in TGFRB1 intron 7 59.239311 310, 310 310, 310
CAMC11.013 Microsatellite 59.911747 338, 346 338, 346
CAMC11.023 Microsatellite 61.260282 265, 277 265, 277
REN147O02 Microsatellite 61.367981 243, 243 243, 243
CAMC11.012 Microsatellite 63.816291 218, 222 218, 222
CAMC11.011 Microsatellite 67.610944 212, 212 212, 212
C11.873 Microsatellite 67.767854 136, 144 136, 144
FH3065 Microsatellite 72.608147 185, 185 185, 185
DGN13 Microsatellite 72.807881 303, 326 303, 326
*Microsatellites are listed according to their position in Ensembl's CanFam 2.0 (July 2008). The position of exons within the CDKN2B-CDKN2A gene 
cluster is provided, along with the position of the gap between contigs 16328 and 16329, and the location of TGFBR1. §The numbers in the genotype 
columns correspond to the PCR product sizes (in base pairs) of the alleles, as determined by the sequencing instrument.
Table 2: CFA11 loss of heterozygosity. (Continued)BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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CDKN2A  gene cluster. Even though the microsatellite
study pointed to loss of heterozygosity rather than com-
plete loss of the region containing CDKN2A  and
CDKN2B, no PCR products could be obtained from the
tumour for the genes themselves, except for CDKN2A
exon 1β. The sequence of this exon showed no differences
with the reference one. A microsatellite within the gene
cluster could be amplified but it was homozygous in
blood and thus non-informative regarding loss of hetero-
zygosity. This microsatellite is 8 kb away from CDKN2A
exon 1β and 3 kb from CDKN2B exon 2, which could not
be detected in the tumour DNA. These results suggest that
two copies of parts of chromosome 11 are present in the
tumour, while other regions are present only once, and
still others, close to the latter, are completely missing. This
complex pattern is reminiscent of the alterations observed
for t(27;11), where TFGBR1  exons 3 to 6 and 9 were
observed, but not the rest of the exons [4]. This agrees also
with the recent observation on the complexity of chromo-
some rearrangements in human tumours [9].
Both approaches, BAC mapping and loss of heterozygos-
ity, point to alterations on canine chromosome 11, in the
region equivalent to human chromosome 9p21 which is
commonly deleted in human tumours [10] and contains
the genes CDKN2B and CDKN2A. The first codes for the
protein p15INK4B, while the second codes for p16INK4A and
p14ARF which are proteins derived from alternate exon 1
sequences and use different reading frames for the com-
mon exon 2 [11,12]. p16INK4A and p14ARF regulate the
retinoblastoma protein 1 (pp105RB1) and the tumour pro-
tein 53 (TP53), respectively. These form part of the two
pathways most commonly disrupted in human tumours.
Recently a new protein, smARF, also coded by CDKN2A,
was identified in mouse and human and localised in the
mitochondria [13]. It has been shown to inhibit cell
growth and proliferation, and to induce apoptosis in a
TP53-independent manner [14,15]. CDKN2A also codes
for the proteins p12 and p16γ which are less well under-
stood [16,17]. In mice, disruption of either p19Arf (the
orthologue of human p14ARF) or p16Ink4b, or both, results
in increased predisposition to tumour development [18-
21]. In humans, homozygous deletions are the most fre-
quent type of mutation involving these genes [22], as
opposed to the combination of mono-allelic deletion fol-
lowed by the mutation of the remaining copy of the gene,
which is the common pattern in other tumour suppressor
genes [23]. However, alterations affecting only one of
p15INK4B, p16INK4A or p14ARF have been reported [11].
Apart from homozygous deletions, 5'CpG methylation
has also been observed in some tumours [12,24-26]. In
human patients with soft tissue sarcomas, loss of
CDKN2B and CDKN2A is associated with reduced sur-
vival [27], while in dogs, absence or reduced levels of
p16INK4A have been reported in melanoma tumours and
cell lines [28], as well as in osteosarcoma cell lines [29]. In
canine non-Hodgkin's lymphoma (NHL), deletion of
p16INK4A or loss of CFA11 have been observed in high-
grade T-cell NHL, without comparable alterations seen in
high-grade B-cell NHL or in low grade tumours [30]. In
this same paper, p16INK4A methylation was observed in a
single low-grade T-cell lymphoma. In addition to this, in
two canine mammary tumour cell lines, CMT12 and
CMT27, no expression of p16INK4A was observed, while in
a third cell line (CMT28) increased expression was
detected [31]. Upon transfection of a complete human
Map of the canine region containing the CDKN2B-CDKN2A locus Figure 3
Map of the canine region containing the CDKN2B-CDKN2A locus. Top, position of CAMC11.026, CAMC11.029, and 
of the gap in the genomic sequence assembly. Middle, microsatellites presenting loss of heterozygosity; also, position of pre-
dicted CDKN2 related exons (darker grey), other unrelated exons (light grey), and canine ESTs in the database (black). Bottom, 
exon designations used here.BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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p16INK4A cDNA, these cell lines lost most of the character-
istics of the transformed phenotype [31]. The sequences of
CMT28 and of canine fibroblast cultured cells were
reported to differ from the reference sequence, although
the nucleotide and the aminoacid sequences are identical
to the canine reference sequences used here for the second
exon of p16INK4A and p14ARF (Figure 7 and Figure 8).
CDKN2A exon 1β codes for the N-terminus portion of
p14ARF. The first amino-acid residues of this protein are
relatively well conserved and have an important role in
binding MDM2 while the rest of the protein, containing a
nucleolar localization signal, is poorly conserved and may
be dispensable [11,32,33]. In chicken, exon 1α of
CDKN2A has been lost and no p16INK4A protein is pro-
duced [34]. Exon 1β is spliced to the still existent exon 2
but the predicted protein terminates at the end of exon 1β,
with no residues from exon 2. In spite of this, the protein
is able to bind MDM2 thus preventing the induction of
TP53 degradation and the inhibition of TP53 expression
[34]. It is therefore likely that exon 1β codes for the amino
acid residues required for p14ARF to perform its normal
role. Moreover, aberrant p16INK4A transcripts have been
observed in tumours [35] and some of them are translated
and are able to function in cell-cycle control [36]. In the
present study only exon 1β of CDKN2A was observed in
LE's fibrosarcoma. It is possible that an abnormal version
of p14ARF  could have been produced; it is unknown
Predicted canine CDKN2B exon 1 amino acid sequences Figure 4
Predicted canine CDKN2B exon 1 amino acid sequences. Alternate Gly residues in the polymorphic region have a grey 
background, while the GlyAspGlyGly repeats are enclosed in a frame and alternate repeats also have a grey background. In LE's 
tumour DNA the exon was missing, but not in peripheral blood where it was heterozygous. Alleles are identified in a simplified 
way (e.g., [2][3]] corresponds to p. [Gly10[2];Gly15_Gly18[3]]).
01.Xenopus_tropicalis          -------MAFNANT-----------------------LCSACARGDVDLA 20 
02.Rattus_norvegicus           -------ML-GGGS--------------------DAGLATAAARGQVETV 22 
03.Mus_musculus                -------ML-GGSS--------------------DAGLATAAARGQVETV 22 
04.Bos_taurus                  -------MLSGGGG--------------------DADLANAAARGQVEAV 23 
05.Macaca_mulatta              MREENKGMPSGGGS--------------------DEGLTSAAARGLVEKV 30 
06.Pan_troglodytes             MREENKGMPSGGGS--------------------DEGLASAAARGLVEKV 30 
07.Homo_sapiens                MREENKGMPSGGGS--------------------DEGLASAAARGLVEKV 30 
08.[[4];[2]]                   MREEATGLLGGGG-------------GDGGGDGGDAGLASASAQGQAETV 37 
09.[[5];[2]]                   MREEATGLLGGGGG------------GDGGGDGGDAGLASASAQGQAETV 38 
10.[[2];[3]]                   MREEATGLLGG-----------GDGGGDGGGDGGDAGLASASAQGQAETV 39 
11.[[5];[3]]                   MREEATGLLGGGGG--------GDGGGDGGGDGGDAGLASASAQGQAETV 42 
12.[[4];[4]]                   MREEATGLLGGGG-----GDGGGDGGGDGGGDGGDAGLASASAQGQAETV 45 
13.[[5];[4]] CanFam2.0         MREEATGLLGGGGG----GDGGGDGGGDGGGDGGDAGLASASAQGQAETV 46 
14.[[5];[5]]                   MREEATGLLGGGGGGDGGGDGGGDGGGDGGGDGGDAGLASASAQGQAETV 50 
15.LE_blood01                  MREEATGLLGGGGG----GDGGGDGGGDGGGDGGDAGLASASAQGQAETV 46 
16.LE_blood01                  MREEATGLLGGGGG--------GDGGGDGGGDGGDAGLASASAQGQAETV 42 
 
 
01.Xenopus_tropicalis          RQMLQSGIPVNATNSHGRTPIQ 42 
02.Rattus_norvegicus           RQLLEAGADPNAVNRFGRRPIQ 44 
03.Mus_musculus                RQLLEAGADPNALNRFGRRPIQ 44 
04.Bos_taurus                  RQLLEAGVDPNRLNRFGRRPIQ 45 
05.Macaca_mulatta              RQLLEAGADPNGVNRFGRRAIQ 52 
06.Pan_troglodytes             RQLLEAGADPNGVNRFGRRAIQ 52 
07.Homo_sapiens                RQLLEAGADPNGVNRFGRRAIQ 52 
08.[[4];[2]]                   RQLLEAGADPNGVNSFGRRPIQ 59 
09.[[5];[2]]                   RQLLEAGADPNGVNSFGRRPIQ 60 
10.[[2];[3]]                   RQLLEAGADPNGVNSFGRRPIQ 61 
11.[[5];[3]]                   RQLLEAGADPNGVNSFGRRPIQ 64 
12.[[4];[4]]                   RQLLEAGADPNGVNSFGRRPIQ 67 
13.[[5];[4]] CanFam2.0         RQLLEAGADPNGVNSFGRRPIQ 68 
14.[[5];[5]]                   RQLLEAGADPNGVNSFGRRPIQ 72 
15.LE_blood01                  RQLLEAGADPNGVNSFGRRPIQ 68 
16.LE_blood01                  RQLLEAGADPNGVNSFGRRPIQ 64 BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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CDKN2B exon 1 genotype determination in dogs of different breeds Figure 5
CDKN2B exon 1 genotype determination in dogs of different breeds. Dye-labelled PCR products were separated by 
capillary electrophoresis. Fragments representing all different sizes were sequenced to confirm the identity of the alleles.
Great dane [[5];[3]]      Bassett hound [[2];[3]] [[5];[3]] 
350 375 400
Size (nt)  
350 375 400
Size (nt)  
German shepherd dog [[5];[3]]    Cairn terrier [[5];[2]] [[5];[4]] 
350 375 400
Size (nt)  
350 375 400
Size (nt)  
Flatcoated retriever [[4];[4]]    Labrador retriever [[5];[3]] [[5];[4]] 
350 375 400
Size (nt)  
350 375 400
Size (nt)  
Boxer  [[5];[4]]     Newfoundland  [[5];[3]]  [[4];[4]] 
350 375 400
Size (nt)  
350 375 400
Size (nt)  
Cardigan Welsh corgi [[4];[2]] [[5];[3]]  Rottweiler [[5];[3]] [[5];[5]] 
350 375 400
Size (nt)  
350 375 400
Size (nt)  
Flatcoated retriever [[4];[4]] [[5];[4]] 
350 375 400
Size (nt)  BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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CDKN2B exon 1 alleles observed in canine blood and tumour samples Figure 6
CDKN2B exon 1 alleles observed in canine blood and tumour samples. Alternate GGC triplets coding for Gly have a 
grey background. The dodecameric nucleotide sequence (GGGGACGGCGGC) coding for the GlyAspGlyGly repeats are 
within a box, with alternate repeats having a grey background. Intronic sequences are in lowercase. Alleles are identified with a 
short version of their description; e.g., [4][2]] stands for g. [109GGC[4];124GGGGACGGCGGC[2]]. The [5][4]] allele corre-
sponds to the reference genome (CanFam2.0).
[[4];[2]] ------------------------------------------------cctcccggcccg 12 
[[5];[2]] ---------------------------------------------------cccggcccg 9 
[[2];[3]] ------------------------------------------------------------ 
[[5];[3]] ---------------------------------------------------cccggcccg 9 
[[4];[4]] ------------------------------------------------------------ 
[[5];[4]] gaaacagggaggcgagtgacgaagctccgctcacggcccgcggtggatcctcccggcccg 60 
[[5];[5]] ------------------------------------------------------------ 
                                                                       
 
[[4];[2]] tccgcgtctgcgggctgcgagATGCGCGAGGAGGCCACGGGCTTGCTCGGCGGCGGCGGC 72 
[[5];[2]] tccgcgtctgcgggctgcgagATGCGCGAGGAGGCCACGGGCTTGCTCGGCGGCGGCGGC 69 
[[2];[3]] ------------ggctgcgagATGCGCGAGGAGGCCACGGGCTTGCTCGGCGGC------ 42 
[[5];[3]] tccgcgtctgcgggctgcgagATGCGCGAGGAGGCCACGGGCTTGCTCGGCGGCGGCGGC 69 
[[4];[4]] ------tctgcgggctgcgagATGCGCGAGGAGGCCACGGGCTTGCTCGGCGGCGGCGGC 54 
[[5];[4]] tccgcgtctgcgggctgcgagATGCGCGAGGAGGCCACGGGCTTGCTCGGCGGCGGCGGC 120 
[[5];[5]] ---------------tgcgagATGCGCGAGGAGGCCACGGGCTTGCTCGGCGGCGGCGGC 45 
                         ***************************************       
 
[[4];[2]] ---------------------------------------GGGGACGGCGGCGGGGACGGC 93 
[[5];[2]] GGC------------------------------------GGGGACGGCGGCGGGGACGGC 93 
[[2];[3]] ---------------------------GGGGACGGCGGCGGGGACGGCGGCGGGGACGGC 75 
[[5];[3]] GGC------------------------GGGGACGGCGGCGGGGACGGCGGCGGGGACGGC 105 
[[4];[4]] ---------------GGGGACGGCGGCGGGGACGGCGGCGGGGACGGCGGCGGGGACGGC 99 
[[5];[4]] GGC------------GGGGACGGCGGCGGGGACGGCGGCGGGGACGGCGGCGGGGACGGC 168 
[[5];[5]] GGCGGGGACGGCGGCGGGGACGGCGGCGGGGACGGCGGCGGGGACGGCGGCGGGGACGGC 105 
                                                 ********************* 
 
[[4];[2]] GGCGACGCGGGCCTGGCCAGCGCCTCGGCGCAGGGGCAGGCGGAGACCGTGCGGCAGCTC 153 
[[5];[2]] GGCGACGCGGGCCTGGCCAGCGCCTCGGCGCAGGGGCAGGCGGAGACCGTGCGGCAGCTC 153 
[[2];[3]] GGCGACGCGGGCCTGGCCAGCGCCTCGGCGCAGGGGCAGGCGGAGACCGTGCGGCAGCTC 135 
[[5];[3]] GGCGACGCGGGCCTGGCCAGCGCCTCGGCGCAGGGGCAGGCGGAGACCGTGCGGCAGCTC 165 
[[4];[4]] GGCGACGCGGGCCTGGCCAGCGCCTCGGCGCAGGGGCAGGCGGAGACCGTGCGGCAGCTC 159 
[[5];[4]] GGCGACGCGGGCCTGGCCAGCGCCTCGGCGCAGGGGCAGGCGGAGACCGTGCGGCAGCTC 228 
[[5];[5]] GGCGACGCGGGCCTGGCCAGCGCCTCGGCGCAGGGGCAGGCGGAGACCGTGCGGCAGCTC 165 
          ************************************************************ 
 
[[4];[2]] CTGGAAGCCGGCGCGGATCCCAACGGAGTCAACAGCTTCGGCAGGCGCCCGATCCAGgta 213 
[[5];[2]] CTGGAAGCCGGCGCGGATCCCAACGGAGTCAACAGCTTCGGCAGGCGCCCGATCCAGgta 213 
[[2];[3]] CTGGAAGCCGGCGCGGATCCCAACGGAGTCAACAGCTTCGGCAGGCGCCCGATCCAGgta 195 
[[5];[3]] CTGGAAGCCGGCGCGGATCCCAACGGAGTCAACAGCTTCGGCAGGCGCCCGATCCAGgta 225 
[[4];[4]] CTGGAAGCCGGCGCGGATCCCAACGGAGTCAACAGCTTCGGCAGGCGCCCGATCCAGgta 219 
[[5];[4]] CTGGAAGCCGGCGCGGATCCCAACGGAGTCAACAGCTTCGGCAGGCGCCCGATCCAGgta 288 
[[5];[5]] CTGGAAGCCGGCGCGGATCCCAACGGAGTCAACAGCTTCGGCAGGCGCCCGATCCAGgta 225 
          ************************************************************ 
 
[[4];[2]] gctggggccccggggcctcgccggcagggggcgcaggaacgcaggggagcggcctccgtg 273 
[[5];[2]] gctggggccccggggcctcgccggcagggggcgcaggaacgcaggggagcggcctccgtg 273 
[[2];[3]] gctggggccccggggcctcgccggcagggggcgcaggaacgcaggggagcggcctccgtg 255 
[[5];[3]] gctggggccccggggcctcgccggcagggggcgcaggaacgcaggggagcggcctccgtg 285 
[[4];[4]] gctggggccccggggcctcgccggcagggggcgcaggaacgcaggggagcggcctcc--- 276 
[[5];[4]] gctggggccccggggcctcgccggcagggggcgcaggaacgcaggggagcggcctccgtg 348 
[[5];[5]] gctggggccccggggcctcgccggcagggggcgcaggaacgcaggggagcggcctcc--- 282 
          *********************************************************    
 
[[4];[2]] ---------------------------------------- 
[[5];[2]] ggacgcgacggg---------------------------- 285 
[[2];[3]] ggacgc---------------------------------- 261 
[[5];[3]] ggacgcgacggg---------------------------- 297 
[[4];[4]] ---------------------------------------- 
[[5];[4]] ggacgcgacggggaccgagagcttcgccgacgtatctgcg 388 
[[5];[5]] ----------------------------------------  BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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whether the remaining exon 1β would have been spliced
to another sequence, generating an abnormal transcript
and, possibly, a shorter version of p14ARF, as is in the
chicken. In the current study, a polymorphism was
observed in exon 2 causing missense mutations in both
p16INK4A and p14ARF. The polymorphic residue is in the
loop joining the second and thitd ankyrin repeats of
p16INK4A. This residue is on the surface of the protein [37].
Although it does not interact with CDK6, it does seem to
have a role in stabilising the structure of p16INK4A [38,39].
In other species this position is occupied by the acidic res-
idues Asp or Glu, so the polar neutral Asn residue seems
to be unique to dogs. However, other structurally related
proteins with ankyrin repeats have Asn in the equivalent
position (e.g., p18) [37].
Polymorphisms in short repeat sequences within coding
exons have been observed before [40,41], whilst somatic
repeat instabilities are well documented in other species
both in tumours and in some degenerative diseases. The
putative first exon of CDKN2B in dogs has a predicted
GlyAspGlyGly repeat that is not found in other species.
This exon is represented in the database by two ESTs [Gen-
Bank: CX985268 and GenBank: DN749168]. The multi-
plicity of alleles in this gene may have resulted from
occasional misalignments during crossover events
between homologous chromosomes, leading to the
expansion and contraction in the number of GGC triplet
and GGGGACGGCGGC dodecamer repeats. No instances
were observed of nonsense mutations in this region, nor
were indels found that would produce shifts in the read-
ing frame. In the case of flat-coated retrievers, which show
a high predisposition to developing histiocytic sarcomas,
cases and controls were found to have a similar distribu-
tion of exon 1 alleles. Moreover, the sequences obtained
from genetic material from blood samples of various
breeds suggest that the variation in the number of Gly res-
Polymorphism in exon 2 of canine CDKN2A in the p14ARF reading frame and alignment to orthologous sequences Figure 7
Polymorphism in exon 2 of canine CDKN2A in the p14ARF reading frame and alignment to orthologous 
sequences. The dog polymorphic residue is highlighted in yellow.
 
Canine p14
ARF and orthologous sequences 
Rattus_norvegicus        GDDDGQRQSGSSPALLWCRFELRGPHHPLPTGARRSAGGLPRHSGSTAPG 50 
Mus_sp.                  GDDDGQRSRSSSSAQLRCRFELRGPHYLLPPGARRSAGRLPGHAGGAARV 50 
Mesocricetus_auratus     GDDDGQHPSSQTAAALRCGTELRGPSHPLPTRARCSTGGLLGNSGDTTPG 50 
BMD                      GHDDGQHPRGPAAAAPRRRPQLCRPRHPHPPCARRGPGGLPGHAGGAAPS 50 
CanFam2.0                GHDDGQHPRGPAAAAPRRQPQLCRPRHPHPPCARRGPGGLPGHAGGAAPS 50 
CMT28_FJ542309           GHDDGQHPRGPAAAAPRRQPQLCRPRHPHPPCARRGPGGLPGHAGGAA-- 48 
NCF_FJ542308             GHDDGQHPRGPAAAAPRRQPQLCRPRHPHPPCARRGPGGLPGHAGGAA-- 48 
Homo_sapiens             GHDDGQRPSGGAAAAPRRGAQLRRPRHSHPTRARRCPGGLPGHAGGAAPG 50 
                         *.****:  . :.*      :*  * :  *. **  .* *  ::*.::   
 
Rattus_norvegicus        RGAAGCARCLGSPAARPGPRAGTSRRRAVFA----------VSTLLRWER 90 
Mus_sp./                 RGSAGCARCLGSPAARLGPRAGTSRHRAIFAFRWVLFVFRWVVFVYRWER 100 
Mesocricetus_auratus     GGAAGCA------------------------------------------- 57 
BMD                      RGAAGRARCLGPPARGPG-------------------------------- 68 
CanFam2.0                RGAAGRARCLGPPARGPG-------------------------------- 68 
CMT28_ FJ542309          --------------------------------------------------  
NCF_ FJ542308            --------------------------------------------------  
Homo_sapiens             RGAAGRARCLGPSARGPG-------------------------------- 68 
                          *:** *                                            
 
Rattus_norvegicus        FPGHRQA 97 
Mus_sp.                  RP-DRRA 106 
Mesocricetus_auratus     -------  
BMD                      -------  
CanFam2.0                -------  
CMT28_ FJ542309          -------  
NCF_ FJ542308            -------  
Homo_sapiens             -------  
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Polymorphism in exon 2 of canine CDKN2A in the p16INK4A reading frame and alignment to orthologous sequences Figure 8
Polymorphism in exon 2 of canine CDKN2A in the p16INK4A reading frame and alignment to orthologous 
sequences. The canine polymorphic position is highlighted in yellow in the loop joining the second and third ankyrin repeats. 
The α helix residues of the ankyrin repeats have a grey background. CanFam2.0 -dog reference genome; BMD -Bernese Moun-





INK4A and orthologous sequences 
Helices                  D3     helix D4               helix D5   helix D6      
Mus_spretus               VMMMGNVHVAALLLNYGADSNCEDPTTFSRPVHDAAREGFLDTLVVLHGS 50 
Mus_musculus              VMMMGNVHVAALLLNYGADSNCEDPTTFSRPVHDAAREGFLDTLVVLHGS 50 
Rattus_norvegicus         VMMMGNVKVAALLLSYGADSNCEDPTTLSRPVHDAAREGFLDTLVVLHQA 50 
Monodelphis_domestica     VMMMGNVRLAAILLQYGAEPNTPDPTTLTLPVHDAAREGFLDTLMLLHRA 50 
Homo_sapiens              VMMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRA 50 
Pan_troglodytes           VMMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRA 50 
Bos_taurus                -MMMGSARVAELLLLHGADPNCADPATLTRPVHDAAREGFLDTLVALHRA 49 
Sus_scrofa                VMMMGSTRVAELLLLHGADPNCEDPATLTRPVHDAAREGFLDTLVVLHRA 50 
BMD                       VMMMGSTRVAQLLLLHGADPNCADPVTLTRPVHDAAREGFLDTLVVLHRA 50 
CanFam2.0                 VMMMGSTRVAQLLLLHGANPNCADPVTLTRPVHDAAREGFLDTLVVLHRA 50 
CMT28_FJ542308            VMMMGSTRVAQLLLLHGANPNCADPVTLTRPVHDAAREGFLDTLVVL--- 47 
NCF_FJ542309              VMMMGSTRVAQLLLLHGANPNCADPVTLTRPVHDAAREGFLDTLVVL--- 47 
Felis_catus               VMMMGSARVAELLLLHGADPNCADPATLTRPVHDAAREGFLDTLVVLHRA 50 
Equus_caballus            VMMMGSVHVAELLLLHGADPNRADPDTLTRPVHDAAREGFL--------- 41 
Takifugu_rubripes         VMMMGSTRVAQILLDHGADPNVADGTTGATPLHDAARSGFLDTVRLLVRF 50 
                           ****..::* :** :**:.*  *  * : *:*****.***          
 
Helices                               helix D7   helix D8                       
Mus_spretus               GARLDVRDAWGRLPLDLAQERGHQDIVRYLR----SAG-CSLCSAGWSLC 95 
Mus_musculus              GARLDVRDAWGRLPLDLAQERGHQDIVRYLR----SAG-CSLCSAGWSLC 95 
Rattus_norvegicus         GARLDVRDAWGRLPLDLALERGHHDVVRYLRYLLSSAGNVSRVTDRHNFC 100 
Monodelphis_domestica     GARLDVRDSWGRLPVDLAEEQGHHLVVAYLR---------EVVRDA---- 87 
Homo_sapiens              GARLDVRDAWGRLPVDLAEELGHRDVARYLR---AAAGGTRGSNHARIDA 97 
Pan_troglodytes           GARLDVRDAWGRLPVDLAEELGHRDVARYLR---AAAGGTRGSNHARIDA 97 
Bos_taurus                GAQLDVRDAWGRLPVDLAEERGHRDVARYLR---AAAEDTEGGSHASADS 96 
Sus_scrofa                GARLDVRDAWGRLPVDLAEERGHRDVAGYLR---ANAGRTEGGSHARSNS 97 
BMD                       GARLDVRDAWGRLPVDLAEERGHGAVAAYLR---AAAGGTESGSHARTEG 97 
CanFam2.0                 GARLDVRDAWGRLPVDLAEERGHGAVAAYLR---AAAGGTESGSHARTEG 97 
CMT28_FJ542308            -------------------------------------------------- 
NCF_FJ542309              -------------------------------------------------- 
Felis_catus               GARLDVRDAWGRLPVDLAEERGHRDIVRYLR---ARTGGTGSGSHTGTDG 97 
Equus_caballus            -------------------------------------------------- 
Takifugu_rubripes         TADPNARDQADRRPVDLARDECHTDVVAFLE---------SL-------- 83 
                                                                             
 
Mus_spretus               TAGNVAQ 102 
Mus_musculus              TAGNVAQ 102 
Rattus_norvegicus         SS----- 102 
Monodelphis_domestica     ------- 
Homo_sapiens              AEGPS-- 102 
Pan_troglodytes           AEGPL-- 102 
Bos_taurus                AEGPA-- 101 
Sus_scrofa                GEDPA-- 102 
BMD                       AEGHA-- 102 
CanFam2.0                 AEGHA-- 102 
CMT28_FJ542308            ------- 
NCF_FJ542309              ------- 
Felis_catus               AEGVA-- 102 
Equus_caballus            ------- 
Takifugu_rubripes         ------- 
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idues and in the number of GlyAspGlyGly repeats is a nor-
mal polymorphism in this species.
p15INK4B, coded by CDKN2B, and the rest of the members
of the inhibitor of kinase 4 (INK4) protein family
(p16INK4A, p18INK4C and p19INK4D) have ankyrin repeats
that play an important role in the folding of the protein
and in intermolecular interactions with other proteins,
such as the cyclin-dependent kinases [39]. p15INK4B and
p16INK4A are similar proteins that appear to be the result of
a gene duplication event [42]; both have 4 ankyrin repeats
and they appear to function in a similar manner and may
be interchangeable [43]. However, p16INK4A  has been
studied in more detail. It is known, for example, that this
protein's loops 1 and 2, as well as some of the ankyrin
repeats themselves, interact with CDK6 [38,44-46]. The
GlyAspGlyGly repeats predicted to exist in canine
p15INK4B  are immediately before helix α1 of the first
ankyrin repeat. Hence the polymorphism may not disrupt
the folding or function of the protein which is dependent
on the ankyrin repeats and the loops connecting them.
These GlyAspGlyGly repeats would introduce a region of
small glycine residues punctuated by charged aspartates
causing a difference in molecular size at the N-terminus of
the protein.
p15INK4B is induced by transforming growth factor, beta 1
(TGFB1) [47-49]; this induction may be direct, through
the binding of TGFB1 to a sequence within the promoter
of CDKN2B [50]. In a previous study we showed that the
breakpoint of the translocation chromosome t(27;11)
involves TGFBR1 [4] which codes for a receptor to TFGB1.
However, the tumour still contained a complete coding
sequence of the gene. It seems, therefore, that the pathway
is disrupted at the level of p15INK4B and p16INK4A through
the homozygous deletion of their coding sequences, while
the possibility still remains that an abnormal p14ARF
could be present.
Conclusion
In fibrosarcomas studied in this work complex rearrange-
ments of canine chromosome 11 were observed, causing
changes in genes in the TGFB – p14INK4B pathway. Study
of CDKN2B showed unusual variants present in exon 1 of
the gene in different breeds of dog, as a result of a simple
repeat sequence. No instances of missense or frameshift-
ing mutations were observed. However, it is possible that
the genomic plasticity of CDKN2B observed here is con-
nected with the rather high frequency of cancers in the
domestic dog.
Methods
Tumours and blood samples
The two tumours, corresponding to two dogs name-coded
LE and ME, have been described previously [4]. Both are
fibrosarcomas from adult Labrador retriever females from
the pet population. Blood samples were obtained from
excess material used for the purpose of clinical diagnostic
studies of dogs admitted to the Queens Veterinary School
Hospital of the University of Cambridge.
Fluorescence-in-situ Hybridisation
Chromosome paints for seven colour FISH and other
combinations of single colour canine chromosome paints
were prepared and used as described previously [51].
BACs were from the RPCI-81 canine BAC library [52], and
DNA's from them were labeled with biotin-dUTP or dig-
oxigenin-dUTP by nick translation. For hybridization,
300 ng of labeled DNA in 1 μl TE representing one chro-
mosome paint probe mix, or 50 ng of labeled BAC DNA,
was mixed with 14 μl hybridization buffer (55% forma-
mide,11% dextran sulphate, 2.2 × SSC, 45 mM sodium
phosphate pH7,1.1× Denhardt's solution (Sigma), 0.5
mM EDTA, 45 μg/ml canine Cot-1 DNA), heated at 70C
for 10 minutes, then left 20–30 minutes at 37°C to allow
pre-annealing of the Cot-1 DNA. Metaphase preparations
on glass slides were denatured, dried and hybridized to
the denatured probes. Hybridization was overnight at
37°C in a humid chamber. Slides were washed two × 5
mins in 50% formamide/50% 2 × SSC at 45C followed by
two × 5 mins in 2 × SSC at 45°C and a final wash in 4 ×
SSC, 0.01% Tween20 before application of fluorochrome-
conjugated antibodies.
Biotin labeled probes were visualized using Cy3-avidin
(single colour FISH) or Cy5-avidin (multi-colour FISH)
(1:500 dilution, Amersham). FITC labeled probes were
visualized using sequential application and washing of
rabbit anti-FITC (1:200) and FITC-labeled goat anti-rabbit
antibodies (1:100). After 20 minutes incubation at 37°C,
excess antibody was washed off by three 5 minute washes
in 4 × T at 42°C. Slides were mounted with Vectashield
containing DAPI and images were captured as before [53].
Fluorescence signals were captured separately as 8-bit
black and white images through appropriate excitation fil-
ters, normalized, and merged into a 24-bit colour image.
10 – 15 metaphases were captured for each probe mix.
DNA extraction form blood
For one of the patients (LE) blood was available and DNA
was extracted using the QIAamp DNA Blood Mini kit
(QIAGEN) according to the manufacturer's instructions.
This same extraction procedure was used for the bloods
used to study the CDKN2B exon 1 polymorphism in 18
breeds.
Loss of heterozygosity analysis
For individual LE, for which tumour and blood DNA was
available, loss of heterozygosity analysis was performed.
Microsatellite markers were chosen along the canine chro-BMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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mosome 11; the location of non CAMC markers and their
primer sequences appear in the dog reference genome in
Ensembl [7]. To fill the gaps between adjacent markers,
and to increase the density in some regions of interest,
such as those around the CDKN2B-CDKN2A locus and
the TFGBR1 gene, additional microsatellites were identi-
fied from the dog reference sequence: appropriate contig
sequences were analysed with Tandem Repeat Finder ver-
sion 4.00 [54] and primers were designed manually or
using Primer3 [55,56]. These markers carry the prefix
CAMC in the name. All PCR reactions had a final volume
of 10 μl, with 1 to 10 ng of genomic DNA as template, 5
U of Taq polymerase (Invitrogen), a final concentration of
0.2 pmol/μl for each primer, 1.5 mM of MgCl2 and 0.25
mM of each dNTP. For markers with the CAMC prefix, the
PCR products were labelled indirectly using a two-step
amplification procedure. For these markers, the forward
marker-specific primer had a T7 universal sequence (5'-
TAATACGACTCACTATAGGG-3') added to its 5' end.
These markers, with forward and reverse primer sequences









































TAGCGCCTGC). For the first PCR these unlabelled
primers were used; 1 μl of these products were then used
as template for a second PCR reaction with a T7 primer
having a D2, D3 or D4 label (Proligo) on its end. The first
PCR reaction was a touch-down PCR with an initial
annealing temperature of 66°C; this temperature was
decreased by 1°C for 12 cycles, followed by 30 cycles with
an annealing temperature of 54°C. For the second PCR 25
cycles were performed with an annealing temperature of
54°C. For all PCRs, each step had a duration of 20 sec. For
markers whose name does not have the prefix CAMC, the
PCR amplifications were performed with a single reaction
using forward primers labelled with D2, D3 or D4 (Pro-
ligo). After PCR amplification, regardless of whether one
or two step reactions had been performed, all PCR prod-
ucts were diluted 1:8 to 1:12 using sterile water. Two
microlitres of each diluted product were mixed with 0.15
μl of D1-labelled GenomeLab DNA size standard 600
(Beckman Coulter) and 30 μl of GenomeLab Sample
Loading Solution containing formamide (Beckman Coul-
ter). The products were then run in a CEQ8000 sequencer
(Beckman Coulter) and genotypes were retrieved with the
instrument's Fragment Analysis software. This same pro-
gram was used to determine loss of heterozygosity, by
comparing the peaks obtained from the blood sample and
for the matching tumour. Loss of heterozygosity was
noted when either peak showed a greater than 30% loss of
signal.
CDKN2B and CDKN2A sequencing
Primers were designed for studying CDKN2B  and
CDKN2A  exonic sequences plus the flanking intronic
bases. The primer names, sequences (5' to 3'), starting and
ending annealing temperatures for touchdown PCR, and
PCR product sizes were as follows. For CDKN2B exon 1
primers 1729 (GAAACAGGGAGGCGAGTGAC) and 1730
(CGCAGATACGTCGGCGAAGC), 70°C to 58°C, 388 bp;
for CDKN2B exon 2 primers 1731 (GAAATGGTCCACCT-
GTCCCTG) and 1732 (CACCGTGACTCAAGTCTCCTG),
72°C to 60°C, 470 bp; for CDKN2A  exon 1b primers
2257 (GAGCTTCCACCCCTAGAAAC) and 2258
(CGGCTCCGAGATCGGAGG), 72°C to 60°C, 526 bp;
and for CDKN2A exon 2 primers 1727 (CTTGTAGCG-
GCATCTGCATGG) and 1728 (TGCTCTGGGCTGCG-
GAAG), 72°C to 62°C, 459 bp. CDKN2B and CDKN2A
sequences are GC-rich, so they were PCR-amplified with
AccuPrime GC-Rich DNA polymerase (Invitrogen) using
Buffer A for that enzyme. PCRs were done in 40 μl, using
6 to 30 ng of genomic DNA, a final concentration ofBMC Veterinary Research 2009, 5:27 http://www.biomedcentral.com/1746-6148/5/27
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02.pmol/μl for each primer and 1.6 U of the polymerase.
All amplifications were done using touchdown-PCR. PCR
products, except for CDKN2B exon 1, were cleaned with
the QIAquick PCR purification kit (QIAGEN), sequenced
with the GenomeLab DTCS kit (Beckman Coulter) and
ran in a CEQ8000 sequencer. Sequences were analysed
and aligned against the canine genomic reference
sequences using the Sequence Analysis and Sequence
Investigator modules on the sequencer. Differences with
respect to the reference sequence were confirmed by
sequencing the complementary strand. CDKN2B exon 1
PCR fragments from tumour samples were cloned and
then sequenced. AccuPrime's GC-rich polymerase proof-
reading activity yields blunt-ended products; to clone the
fragments into the PCR4-TOPO vector of the TOPO TA
Cloning Kit for Sequencing (Invitrogen) a 3' A-overhang
was incorporated to the PCR products by incubating them
with 1 μl of Taq polymerase (Invitrogen) at 72°C for 10
min. Sequencing reactions with the GenomeLab DTCS kit
were performed according to the manufacturer's protocol
for plasmid templates except that betaine (Sigma) was
added to a final concentration of 1 M. The reference
sequences used were CanFam 2.0, assembly May 2006,
Genebuild Sep 2008 [7,8] for the canine genome; [EMBL:
FM946072] for CDKN2B  and [EMBL: FM883643] for
p14ARF/CDKN2A. Polymorphisms and mutations in these
sequences are described following the recommended
nomenclature [57,58].
CDKN2B exon 1 polymorphism search
To determine the CDKN2B exon 1 alleles present in a col-
lection of dog DNAs of different breeds, the exon was
amplified, along with the flanking intronic sequences,
using a D4 (Sigma) labelled forward primer 1729 and an
unlabelled reverse primer 1730. The length of the prod-
uct, according to the reference sequence in CanFam2.0 is
388 bp [7]. PCRs were performed using the KAPA2G
Robust PCR Kit (Kapabiosystems, Cape Town, South
Africa), with buffer B and Kapa Enhancer 1, in a volume
of 10 μl, with a minimum of 8 ng of template and a touch-
down-PCR starting with an annealing temperature of
72°C, and decreasing by 1°C per cycle to 59°C, followed
by 25 cycles with an annealing temperature of 58°C.
Annealing, extension (at 72°C) and denaturation (at
95°C) were 20 sec long each. The products were diluted
1:8 with sterile water and loaded on a CEQ8000
sequencer (Beckman Coulter) to determine the size of the
PCR products with the Fragment Analysis module of the
instrument; 18.25% of the samples were retested to con-
firm the results. 22.63% of the samples, representing the
different allele sizes observed, were amplified again from
genomic DNA and sequenced directly with the Genom-
eLab DTCS kit following the procedure recommended by
the manufacturer for GC-rich sequences. Cleaned prod-
ucts were separated on the CEQ8000 at 60°C and results
analysed as in the sequences described in the previous sec-
tion. Multiple alignments of nucleotide and predicted
amino acid sequences were done with ClustalW2 [59] at
the EMBL-EBI website [60] or using JalView 2.3 [61] and
then manually edited. GenBank accession numbers for
p15INK4B amino acid sequences used for the alignments
were [Xenopus tropicalis GenBank: AAH75575.1,  Rattus
norvegicus GenBank: EDL97746.1, Mus musculus GenBank:
AAH02010.1,  Bos taurus GenBank: NP_001069362,
Macaca mulatta GenBank: XP_001107263.1, Pan troglo-
dytes  GenBank: ENSPTRP00000035618,  Homo sapiens
GenBank: P42772]. The sequences for p16INK4A were [Tak-
ifugu rubripes GenBank: CAC12808.1, Monodelphis domes-
tica  GenBank: AAC23669.1,  Bos taurus GenBank:
XP_612365.1, Equus caballus GenBank: AAC97110.1, Sus
scrofa  GenBank: CAB65454.1,  Mus spretus GenBank:
AAD00236.1,  Rattus norvegicus GenBank: AAL76339.1,
Mus musculus UniProt: P51480-1, Felis catus GenBank:
BAA33540.1,  Pan troglodytes GenBank: XP_520513.1,
Homo sapiens GenBank: NP_478104.1, CMT28 GenBank:
FJ542308.1, NCF GenBank: FJ542309.1] and for p14ARF
[Mesocricetus auratus GenBank: AAN75824.1, Rattus nor-
vegicus  GenBank: AAL76336.1,  Mus sp. GenBank:
AAB35770.1, Homo sapiens GenBank: NP_478102.1].
In the flat-coated retrievers allele distribution between
cases and controls was compared using a Monte Carlo
simulation of the chi-square test and grouping together
columns with expected values lower than 5, as imple-
mented in the T2 test of the program Clump [62]; the level
of significance was determined by performing 10000 sim-
ulations.
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